Asterias Biotherapeutics (AST) Misses Q1 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts AST Hot Sheet
Join SI Premium – FREE
Asterias Biotherapeutics (NYSE: AST) reported Q1 EPS of ($0.27), $0.13 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $870 thousand.
For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SPS Commerce (SPSC) Tops Q3 EPS by 16c; Offers Guidance
- OneSpan Inc. (OSPN) Tops Q3 EPS by 6c ; Offers Guidance
- Methanex (MEOH) Tops Q3 EPS by 87c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
